Metastasis is a leading cause of breast cancer mortality. The induction of epithelial-to-mesenchymal transition (EMT) and complex oncogenic signaling is a vital step in the evolution of highly metastatic and therapeutically-intractable breast cancer; necessitating novel target discovery or development of therapeutics that target metastatic breast cells (MBCs). | Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem celllike phenotype by up-regulating miR-335 in metastatic breast cancer in vitro and in vivo
